A brief medication guide for the targeted drug crizotinib (XALKORI)

Crizotinib (English generic name:crizotinib, trade name: XALKORI) is an innovative oral targeted anti-cancer drug that brings new treatment hope to patients carrying ALK or ROS1 gene mutations. To ensure that patients can use this drug safely and effectively, the following concise medication guidelines have been developed.

1. Scope of indications

Crizotinib is mainly suitable for the following patient groups:

1. Patients diagnosed with ALK-positive or ROS1-positive locally advanced or metastatic non-small cell lung cancer.

2. Children and young patients 1 year old and above with ALK-positive relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).

3. Adult and pediatric patients 1 year old and above with ALK-positive unresectable, recurrent or refractory inflammatory myofibroblastic tumor (IMT).

2. Medication methods and dosage

1. For adult patients with lung cancer orIMT: It is recommended to take 250mg twice a day, and you can choose to take it in the morning and evening on an empty stomach or with food. Swallow tablets whole and do not chew or dissolve.

2. For pediatric patients with lymphoma orIMT: The recommended dose is 280 mg/m², taken orally twice daily. You can also choose to take it in the morning and evening on an empty stomach or with food. Swallow the tablet whole without chewing or dissolving it.

1. Medication precautions

1. Liver function monitoring: Since crizotinib is mainly metabolized in the liver, patients with liver damage should use it with caution and monitor liver function regularly.

2. Visual abnormalities: Blurred vision, floaters and other visual impairments may occur during medication. Please seek medical attention in time.

3. Blood system monitoring: Regularly monitor blood routine, paying special attention to changes in white blood cells, platelets and other indicators.

4. Heart health: Patients with a history of heart disease should pay close attention to signs and symptoms of heart failure, such as difficulty breathing, edema, etc.

5. Risk of infection: Crizotinib may increase the risk of infection. Please try to avoid contact with infected people.

4. Contraindications and caution in use

This drug is contraindicated in those who are allergic to crizotinib or any of its ingredients.

5. Drug interaction tips

Please avoid combined use with strong inhibitors or inducers of CYP3A. If this cannot be avoided, please adjust the dose of crizotinib under the guidance of your doctor.

6. Special medication tips

Crizotinib is a prescription drug and must be used in medical institutions with experience in its use and under the guidance of specific professional technicians. If you need to seek medical attention while taking this medicine, be sure to tell your doctor, pharmacist, and nurse that you are taking crizotinib.

In summary, crizotinib provides an effective treatment option for patients with ALK-positive or ROS1-positive non-small cell lung cancer. When using, please be sure to strictly abide by medical instructions and pay attention to monitor adverse reactions to ensure the safety and effectiveness of treatment. Currently, the original drug of this drug is on the market in China and can be reimbursed by medical insurance. At the same time, its generic drugs are also available in overseas markets, providing patients with more affordable treatment options.